CHEERS: VR-based Intervention for Cognitive Restoration

Sponsor
Chungnam National University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05653596
Collaborator
(none)
200
1
2
60.7
3.3

Study Details

Study Description

Brief Summary

The aim of this study is to test the efficacy of a nature-based cognitive intervention to restore cognitive function among women treated for breast cancer.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Virtual reality-based cognitive intervention
N/A

Detailed Description

Cognitive dysfunction is a kind of cluster of commonly reported neurotoxic symptoms following cancer diagnosis and treatment, especially chemotherapy. Our previous studies found that breast cancer patients and survivors had greater difficulties in performing attention, working memory, and executive function tasks and had persistent neural inefficiency of an executive network of the brain than disease and treatment counterparts.

The aim of this study is to test the efficacy of a nature-based cognitive intervention to restore cognitive function among women with cognitive complaints after breast cancer treatment. All participants will receive the initial screening to verify their cognitive status and then will be randomly assigned to the experimental or control group. The experimental group will receive a 4-week cognitive intervention by using a VR headset. Each VR content includes 10-12 video scenes with visual and auditory stimuli that were generated from nature.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
200 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Supportive Care
Official Title:
Virtual Reality-Based Cognitive Intervention for Women With Cognitive Complaints Following Breast Cancer Treatment
Actual Study Start Date :
Dec 10, 2019
Anticipated Primary Completion Date :
Dec 31, 2024
Anticipated Study Completion Date :
Dec 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Experimental: VR restorative intervention

Individuals who are assigned to the experimental group will receive a 4-week VR-based cognitive intervention.

Behavioral: Virtual reality-based cognitive intervention
This intervention consists of 12 different VR contents that were developed for this trial. Each content includes 10-12 scenes with visual and auditory stimuli generated from nature. Participants will view 3D nature videos using a VR headset for 20 minutes every other day, three times per week for one month.

No Intervention: Control: Usual care

Individuals who are assigned to the control group will receive the usual care and then receive the same intervention as they wish.

Outcome Measures

Primary Outcome Measures

  1. Central Nervous System Vital Signs (CNSVS) [Cognitive function will be assessed at baseline]

    The CNSVS will be used to assess global and domain-specific cognitive function

  2. Central Nervous System Vital Signs (CNSVS) [Cognitive function will be assessed at 4 weeks after baseline (immediate post-intervention)]

    The CNSVS will be used to assess global and domain-specific cognitive function

  3. Central Nervous System Vital Signs (CNSVS) [Cognitive function will be assessed at 8 weeks after baseline (4 weeks after intervention)]

    The CNSVS will be used to assess global and domain-specific cognitive function

  4. Functional Assessment of Cancer Therapy-Cognitive [Perceived cognitive function will be assessed at baseline]

    The FACT-Cog will be used to assess self-reported effectiveness in cognitive function

  5. Functional Assessment of Cancer Therapy-Cognitive [Perceived cognitive function will be assessed at 4 weeks after baseline (immediate post-intervention)]

    The FACT-Cog will be used to assess self-reported effectiveness in cognitive function

  6. Functional Assessment of Cancer Therapy-Cognitive [Perceived cognitive function will be assessed at 8 weeks after baseline (4 weeks after intervention)]

    The FACT-Cog will be used to assess self-reported effectiveness in cognitive function

Secondary Outcome Measures

  1. Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) [Fatigue will will be assessed at baseline, 4 weeks (immediate post-intervention), and 8 weeks (4 weeks after intervention)]

    The FACIT-F will be used to assess experience and impact of fatigue

  2. Patient Health Questionnaire (PHQ) [Depression will be assessed at baseline, 4 weeks (immediate post-intervention), and 8 weeks (4 weeks after intervention)]

    The PHQ will be used to assess depressed mood

  3. Pittsburgh Sleep Quality Index (PSQI) [Sleep problems will be assessed at baseline, 4 weeks (immediate post-intervention), and 8 weeks (4 weeks after intervention)]

    The PSQI will be used to assess sleep problems

  4. Functional Assessment of Cancer Therapy-General (FACT-G) [Quality of life will be assessed at baseline, 4 weeks (immediate post-intervention), and 8 weeks (4 weeks after intervention)]

    The FACT-G will be used to assess health-related quality of life

  5. Perceived Restorativeness for Activities Scale (PRAS) [Perceived restorativeness will be assessed at baseline, 4 weeks (immediate post-intervention), and 8 weeks (4 weeks after intervention)]

    The PRAS will be used to assess perceived restorativeness of their activities engaged to improve cognition

Eligibility Criteria

Criteria

Ages Eligible for Study:
19 Years to 64 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Being treated with chemotherapy for breast cancer

  • Having affirmative responses to three questions about cognitive problems and their impact on daily performance

  • Having FACT-Cog scores of 58 or less

  • Having Mini-Cog scores of 3 and higher

  • Having the ability to read, understand or respond to questionnaires and cognitive assessment

  • Being willing to participate and able to provide written informed consent

Exclusion Criteria:
  • Having metastatic breast cancer

  • Having Patient Health Questionnaire-2 score of 3 and higher

  • Being diagnosed with neurological disorders such as dementia, multiple sclerosis, or traumatic brain injury

  • Having epilepsy or seizure

  • Having 'quite a bit' or 'extremely' severe level of nausea and vomiting

  • Having visual or hearing impairments

  • Having other problems that prevent them from wearing the VR headset

Contacts and Locations

Locations

Site City State Country Postal Code
1 Cognitive Health Education and Research Center Daejeon Korea, Republic of 48105

Sponsors and Collaborators

  • Chungnam National University

Investigators

  • Principal Investigator: Mi Sook Jung, PhD, Chungnam National University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Mi Sook Jung, Associate professor, Chungnam National University
ClinicalTrials.gov Identifier:
NCT05653596
Other Study ID Numbers:
  • ChungnamNU.J1
First Posted:
Dec 16, 2022
Last Update Posted:
Dec 16, 2022
Last Verified:
Dec 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 16, 2022